Journal article
Choices of Methodology in Pharmacoeconomic Studies
Abstract
OBJECTIVES: The goal of this paper is to evaluate the comparative value of economic methodologies in assessing the benefit of a new cytoprotective agent (amifostine) delivered before cisplatin/cyclophosphamide in the treatment of ovarian cancer.
BACKGROUND: Data from a randomized controlled multinational multicenter ovarian cancer trial were used as the basis for a retrospective pharmacoeconomic analysis. Trial results demonstrated amifostine …
Authors
Longo CJ
Journal
Medical Care, Vol. 37, No. 4, pp. as32–as35
Publisher
Wolters Kluwer
Publication Date
4 1999
DOI
10.1097/00005650-199904001-00006
ISSN
0025-7079
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AmifostineAntineoplastic Agents, AlkylatingAttitude of Health PersonnelCanadaCisplatinCost-Benefit AnalysisCyclophosphamideEconomics, PharmaceuticalFemaleHealth Services ResearchHumansMulticenter Studies as TopicNeutropeniaOutcome Assessment, Health CareOvarian NeoplasmsQuality-Adjusted Life YearsRadiation-Protective AgentsRandomized Controlled Trials as TopicRetrospective Studies